R&D Insights: How GSK plc and Geron Corporation Allocate Funds

R&D Spending: A Tale of Two Companies

In the ever-evolving landscape of pharmaceutical innovation, research and development (R&D) spending is a critical indicator of a company's commitment to future growth. Over the past decade, GSK plc and Geron Corporation have demonstrated contrasting approaches to R&D investment.

GSK plc: A Steady Climb

From 2014 to 2023, GSK plc has consistently increased its R&D expenses, with a notable 80% rise from approximately $3.45 billion in 2014 to $6.22 billion in 2023. This steady climb underscores GSK's robust strategy to maintain its competitive edge in the pharmaceutical industry.

Geron Corporation: A Focused Approach

In contrast, Geron Corporation's R&D spending, while significantly smaller, has seen a remarkable increase of over 500% from 2014 to 2023. This focused investment reflects Geron's strategic emphasis on niche areas within biotechnology.

These insights reveal the diverse strategies employed by pharmaceutical companies in their quest for innovation.